Business Context and Reporting Period
This Form 8-K filing by Alkermes Plc. (the "Company") reports a material definitive agreement completed on April 10, 2015. The report was filed on April 13, 2015. The Company, incorporated in Ireland, announced the sale of specific assets and rights to Recro Pharma, Inc. ("Recro") and Recro Pharma LLC.
Key Financial Metrics and Transaction Details
The transaction involved the sale of a manufacturing facility in Gainesville, GA, associated manufacturing and royalty revenue, and global rights to IV/IM and parenteral forms of Meloxicam. The consideration received by the Company includes:
- Initial Cash Payment: $50 million.
- Working Capital Adjustment: A payment relating to net working capital (specific amount not disclosed).
- Equity Warrant: A seven-year warrant to purchase 350,000 shares of Recro common stock at an exercise price of $19.46 per share.
- Future Royalties: Low double-digit royalties on net sales of IV/IM and parenteral forms of Meloxicam.
- Milestone Payments: Up to $120 million contingent upon achieving certain regulatory and sales milestones.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company's overall operations, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Material Changes and Related Parties
The disposition represents a material change in the Company's asset base, removing the Gainesville manufacturing facility and the associated Meloxicam product rights. A related party transaction element exists: Geraldine Henwood, President and CEO of Recro, was a member of the Company's Board of Directors prior to her resignation on March 7, 2015, the same date the Purchase Agreement was entered into.
Outlook, Risks, and Contingencies
The Company expects to receive future contingent consideration based on the performance of the sold assets. Specifically, the receipt of up to $120 million in milestone payments is contingent on future regulatory and sales achievements. Additionally, the Company will receive ongoing royalties on net sales of the transferred Meloxicam products. Pro forma financial information regarding the impact of this transaction is not included in this filing but is scheduled to be filed by amendment no later than April 16, 2015.
Investor Verification Checklist
- Verify the exact amount of the net working capital adjustment payment.
- Review the upcoming pro forma financial information (Exhibit 99.1) to understand the transaction's impact on the Company's financial position.
- Confirm the specific regulatory and sales milestones required to trigger the up to $120 million in milestone payments.
- Assess the valuation of the seven-year warrant based on current and projected Recro stock prices.
- Review the full Purchase and Sale Agreement (Exhibit 2.1) for additional covenants or conditions.